IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell malignancies
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 24 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 24 samples: 24 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignanciesNature communications · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE225755_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA937281 and SRA study SRP423776. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 24 sample titles: 24 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7055521 NALM6, shCTRL, rep 1 (atac)
- GSM7055522 NALM6, shCTRL, rep 2 (atac)
- GSM7055523 NALM6, shIKZF1, rep 1 (atac)
- GSM7055524 NALM6, shIKZF1, rep 2 (atac)
- GSM7055525 REH, shCTRL, rep 1 (atac)
- GSM7055526 REH, shCTRL, rep 2 (atac)
- GSM7055527 REH, shIKZF1, rep 1 (atac)
- GSM7055528 REH, shIKZF1, rep 2 (atac)
- GSM7055529 SUP-B15, shCTRL, rep 1 (atac)
- GSM7055530 SUP-B15, shCTRL, rep 2 (atac)
- GSM7055531 SUP-B15, shIKZF1, rep 1 (atac)
- GSM7055532 SUP-B15, shIKZF1, rep 2 (atac)
- GSM7055539 NALM6, shCTRL, rep 1 (rna)
- GSM7055540 NALM6, shCTRL, rep 2 (rna)
- GSM7055541 NALM6, shIKZF1, rep 1 (rna)
- GSM7055542 NALM6, shIKZF1, rep 2 (rna)
- GSM7055543 REH, shCTRL, rep 1 (rna)
- GSM7055544 REH, shCTRL, rep 2 (rna)
- GSM7055545 REH, shIKZF1, rep 1 (rna)
- GSM7055546 REH, shIKZF1, rep 2 (rna)
- GSM7055547 SUP-B15, shCTRL, rep 1 (rna)
- GSM7055548 SUP-B15, shCTRL, rep 2 (rna)
- GSM7055549 SUP-B15, shIKZF1, rep 1 (rna)
- GSM7055550 SUP-B15, shIKZF1, rep 2 (rna)
- GSE225754 IKAROS modulates CD19 surface expression and CD19-directed CAR-T response [RNA-seq] 12 samples shares ikaros, cd19
- GSE225752 IKAROS modulates CD19 surface expression and CD19-directed CAR-T response [ATAC-seq] 12 samples shares ikaros, cd19
- GSE270185 Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia 249 samples shares cd19, therapies
- GSE244184 Degradation of Ikaros prevents epigenetic progression of T cell exhaustion in novel antigen-specific assay 15 samples shares ikaros, antigen
- GSE277818 Targeting PRC2 enhances the antitumor cytotoxic capacity of anti-CD19 CAR-T cells against hematological malignancies 12 samples shares cd19, malignancies
- GSE244183 Degradation of Ikaros prevents epigenetic progression of T cell exhaustion in novel antigen-specific assay [bulk ATAC-seq] 11 samples shares ikaros, antigen
- GSE310003 Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs 8 samples shares cd19, antigen
- GSE244180 Degradation of Ikaros prevents epigenetic progression of T cell exhaustion in novel antigen-specific assay [scRNA-seq] 2 samples shares ikaros, antigen
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.